



Announcement Summary

Name of entity

MAYNE PHARMA GROUP LIMITED

Announcement type

New announcement

Date of this announcement

24/5/2024

ASX Security code and description of the class of +securities the subject of the buy-back

MYX : ORDINARY FULLY PAID

The type of buy-back is:

On market buy-back

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our buy-back.

1.2 Registration number type

ABN

Registration number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

New announcement

1.5 Date of this announcement

24/5/2024

1.6 ASX Security code and description of the class of +securities the subject of the buy-back

MYX : ORDINARY FULLY PAID



Part 2 - Type of buy-back

2.1 The type of buy-back is:
On market buy-back



Part 3 - Buy-back details

Part 3A - Details of +securities, price and reason

3A.1 Total number of +securities on issue in the class of +securities to be bought back

81,245,827

3A.4 Does the entity intend to buy back a minimum number of +securities

No

3A.5 Does the entity intend to buy back a maximum number of securities

No

3A.6 Name of broker or brokers who will offer to buy back +securities on the entity's behalf

Broker name:

Jefferies (Australia) Securities Pty Ltd

3A.9 Are the +securities being bought back for a cash consideration?

Yes

3A.9a Is the price to be paid for +securities bought back known?

No

3A.9a.1 In what currency will the buy-back consideration be paid?

AUD - Australian Dollar

Part 3B - Buy-back restrictions and conditions

3B.1 Does the buy-back require security holder approval?

No



Part 3C - Key dates

On-market buy-back

3C.2 Proposed buy-back start date

24/5/2024

3C.3 Proposed buy-back end date

29/11/2024

Part 3D - Other Information

3D.1 Any other information the entity wishes to notify to ASX about the buy-back

Mayne Pharma confirms that it has today lodged an Appendix 3F related to the expiration of the original up to 10 percent on-market share buy-back program which commenced on 25 May 2023 and expired on 24 May 2024. This Appendix 3C is relating to the up to 15 percent on-market buy-back program approved by Mayne Pharma shareholders at its AGM on 30 November 2023. This program will expire on 29 November 2024 unless otherwise notified.